BLFS Valuation

BioLife Solutions Inc

Add to Watchlist

Advanced Chart

24.340

-0.98(-3.870%)1D

Overview
Forecast
Valuation
Earnings

BLFS Relative Valuation

BLFS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BLFS is overvalued; if below, it's undervalued.

Historical Valuation

BioLife Solutions Inc (BLFS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 10.78 is considered Undervalued compared with the five-year average of -1566.12. The fair price of BioLife Solutions Inc (BLFS) is between 36.50 to 50.27 according to relative valuation methord. Compared to the current price of 24.34 USD , BioLife Solutions Inc is Undervalued By 33.32%.

Relative Value

Fair Zone

36.50-50.27

Current Price：24.34

33.32%

Undervalued

-3245.33

Trailing

Forward

40.54

EV/EBITDA

BioLife Solutions Inc. (BLFS) has a current EV/EBITDA of 40.54. The 5-year average EV/EBITDA is 91.80. The thresholds are as follows: Strongly Undervalued below -132.63, Undervalued between -132.63 and -20.41, Fairly Valued between 204.01 and -20.41, Overvalued between 204.01 and 316.23, and Strongly Overvalued above 316.23. The current Forward EV/EBITDA of 40.54 falls within the Historic Trend Line -Fairly Valued range.

-450.58

EV/EBIT

BioLife Solutions Inc. (BLFS) has a current EV/EBIT of -450.58. The 5-year average EV/EBIT is -116.95. The thresholds are as follows: Strongly Undervalued below -1117.23, Undervalued between -1117.23 and -617.09, Fairly Valued between 383.20 and -617.09, Overvalued between 383.20 and 883.34, and Strongly Overvalued above 883.34. The current Forward EV/EBIT of -450.58 falls within the Historic Trend Line -Fairly Valued range.

10.78

BioLife Solutions Inc. (BLFS) has a current PS of 10.78. The 5-year average PS is 8.87. The thresholds are as follows: Strongly Undervalued below 1.25, Undervalued between 1.25 and 5.06, Fairly Valued between 12.68 and 5.06, Overvalued between 12.68 and 16.50, and Strongly Overvalued above 16.50. The current Forward PS of 10.78 falls within the Historic Trend Line -Fairly Valued range.

43.59

P/OCF

BioLife Solutions Inc. (BLFS) has a current P/OCF of 43.59. The 5-year average P/OCF is 57.65. The thresholds are as follows: Strongly Undervalued below -161.66, Undervalued between -161.66 and -52.00, Fairly Valued between 167.31 and -52.00, Overvalued between 167.31 and 276.96, and Strongly Overvalued above 276.96. The current Forward P/OCF of 43.59 falls within the Historic Trend Line -Fairly Valued range.

481.63

P/FCF

BioLife Solutions Inc. (BLFS) has a current P/FCF of 481.63. The 5-year average P/FCF is 5.13. The thresholds are as follows: Strongly Undervalued below -984.30, Undervalued between -984.30 and -489.59, Fairly Valued between 499.84 and -489.59, Overvalued between 499.84 and 994.55, and Strongly Overvalued above 994.55. The current Forward P/FCF of 481.63 falls within the Historic Trend Line -Fairly Valued range.

BioLife Solutions Inc (BLFS) has a current Price-to-Book (P/B) ratio of 3.35. Compared to its 3-year average P/B ratio of 2.69 , the current P/B ratio is approximately 24.62% higher. Relative to its 5-year average P/B ratio of 3.28, the current P/B ratio is about 2.16% higher. BioLife Solutions Inc (BLFS) has a Forward Free Cash Flow (FCF) yield of approximately 0.93%. Compared to its 3-year average FCF yield of -1.73%, the current FCF yield is approximately -153.86% lower. Relative to its 5-year average FCF yield of -1.56% , the current FCF yield is about -159.88% lower.

3.35

P/B

Median3y

2.69

Median5y

3.28

0.93

FCF Yield

Median3y

-1.73

Median5y

-1.56

Competitors Valuation Multiple

The average P/S ratio for BLFS's competitors is 52.68, providing a benchmark for relative valuation. BioLife Solutions Inc Corp (BLFS) exhibits a P/S ratio of 10.78, which is -79.54% above the industry average. Given its robust revenue growth of 28.94%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

BLFS.O

BioLife Solutions Inc

Establishment Labs Holdings Inc

Integra Lifesciences Holdings Corp

Pulse Biosciences Inc

291.15

1.09B

Performance Decomposition

Market capitalization of BLFS decreased by 5.95% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -28.20 to -62.30.

The secondary factor is the Revenue Growth, contributed 28.94%to the performance.

Overall, the performance of BLFS in the past 1 year is driven by Margin Expansion. Which is more sustainable.

28.94%

19.72M → 25.42M

Revenue Growth

120.92%

-28.20 → -62.30

Margin Expansion

-155.81%

107.50 → -60.00

P/E Change

-5.95%